Leadership changes at Quince Therapeutics, Inc. (2026)

Departing: Dirk Thye, Chief Executive Officer and Chief Medical Officer, effective 2026-10-08

As previously announced, effective as of October 8, 2026, Dirk Thye, M.D., resigned as Chief Executive Officer and Chief Medical Officer, as well as a director, of Quince Therapeutics, Inc., which will be renamed IRulya Therapeutics Inc. effective at 4:01 p.m., Eastern Time, on October 9, 2026 (the " Company "), and Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer of the Company.

Appointed: Brigette Roberts, Chief Executive Officer, effective 2026-10-08

Effective October 8, 2026 (the " Effective Date "), the Board of Directors (the " Board ") of the Company appointed Brigette Roberts, M.D., as Chief Executive Officer of the Company.

Appointed: John Militello, Chief Financial Officer

Effective as of the Effective Date, John Militello, CPA, was appointed as Chief Financial Officer of the Company.

Appointed: Keith Fandrick, Chief Operating Officer

Effective as of the Effective Date, Keith Fandrick was appointed as Chief Operating Officer of the Company.

Also stated in this filing

• Brigette Roberts, M.D., age 50 Dr. Roberts has served as the Company's Chief Corporate Affairs Officer and member of the Board since May 2026.
• Prior to that, she served as the Chief Executive Officer and member of the Board of Directors of Orphai Therapeutics, Inc. ("Orphai") from May 2021 until May 2026, and prior to that she served as the Chief Medical Officer of Orphai from February 2021 until May 2021.
• During her time at Orphai, Dr. Roberts built a differentiated pulmonary franchise centered on LAM-001, an inhaled formulation of rapamycin for pulmonary vascular and fibrotic lung diseases, initiated two Phase 2 studies of LAM-001, secured United States and European Union orphan drug designations for LAM-001 across multiple indications and raised more than $45 million in new private investment.
• Prior to Orphai, Dr. Roberts served as an Entrepreneur in Residence at Fortress Biotech from 2017 to January 2021 where she identified new assets to spin into new biotechnology companies.
• Prior to that, Dr. Roberts spent over 15 years as a healthcare investor and portfolio manager including at CDP Capital, Angel Lane Principal Strategies, YYC Capital (which she founded), Third Point, LLC and DKR Capital.
• Dr. Roberts also served as a director of Ligand Pharmaceuticals from December 2005 to February 2007.

Reported

The 2026 Plan has an initial share reserve equal to (i) 821,872 shares of the Company's common stock, par value $0.001 per share (" common stock ") plus up to (ii) 1,377,845 shares of common stock subject to outstanding stock awards granted under the Company's 2019 Equity Incentive Plan, the Novesto Inc. 2019 Equity Incentive Plan, the Company's 2022 Inducement Plan, the Orphai Therapeutics Inc. 2026 Stock Incentive Plan and the Orphai Therapeutics Inc. 2013 Employee, Director and Consultant Equity Incentive Plan (collectively, the " Prior Plans ") that, after the date that the 2026 Plan becom

Also stated in this filing

• On October 6, 2026, Quince Therapeutics, Inc. (the "Company"), held a special meeting of stockholders (the "Special Meeting").
• At the Special Meeting, the Company's stockholder approved (i) the Company's 2026 Equity Incentive Plan (the "2026 Plan") and (ii) the Company's 2026 Employee Stock Purchase Plan (the "2026 ESPP").
• The 2026 ESPP has an initial share reserve equal to 142,045 shares of common stock.
• The Board previously approved the 2026 Plan and 2026 ESPP on July 29, 2026 and July 30, 2026, respectively, subject to stockholder approval.
• A summary of the principal features of the 2026 Plan and 2026 ESPP are set forth under the headings "Proposal No. 4 - Approval of the 2026 Equity Incentive Plan" and "Proposal No. 5 - Approval of the 2026 ESPP" contained in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on August 25, 2026 (the "Proxy Statement").

Appointed: Catherine Bonuccelli, Director

Upon the effectiveness of the respective appointments, it is expected that; Ms. Bonuccelli will serve as a Class I director and as member of the Audit Committee and Compensation Committee of the Board; Ms. Patterson will serve as a Class III director and as chair of the Audit Committee and as chair of the Compensation Committee of the Board; Mr. Valentine will serve as a Class I director and as a member of the Audit Committee and as chair of the Nominating and Corporate Governance Committee of the Board; and Mr. Wise will serve as a Class II director and as a member of the Nominating and Corpo

Also stated in this filing

• For a description of the Conversion Proposal, the Minimum Price Proposal and the Authorized Shares Proposal, please refer to the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on August 25, 2026 (the "Definitive Proxy Statement").
• The decisions of the Resigning Directors to resign were not the result of any disagreement with the Company on any matter relating the Company's operations, policies, or practices.
• Conditional Appointments of New Directors In connection with the foregoing, on October 1, 2026, the Board approved the conditional appointments of each of Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise (collectively, the "Incoming Directors") to the Board, effective as of the Effective Time.
• Catherine M. Bonuccelli, M.D., age 68 Dr. Bonuccelli has served as principal and owner of CMB Life Sciences Consulting LLC since May 2024.
• Previously, Dr. Bonuccelli served as Chief Medical Officer of Bellus Health (acquired by GSK plc (NYSE: GSK) in 2023) from August 2019 to April 2024, where she advanced an asset for refractory chronic cough into Phase 3 prior to the company's acquisition.

Reported

Conditional Resignations of Dirk Thye and Brendan Hannah On July 29, 2026, each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the " Company "), and a member of the Company's board of directors (the " Board "), and Brendan Hannah, the Company's Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company (including, with respect to Mr. Thye, as a member of the Board), in each case effective as of two business days following the conclusion of the Company's

Also stated in this filing

• For a description of the Conversion Proposal, the Minimum Price Proposal and the Authorized Share Proposal, please refer to the Company's preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the "SEC") on July 31, 2026 (the "Preliminary Proxy Statement").
• Conditional Appointments of Brigette Roberts, John Militello and Keith Fandrick In connection with the foregoing, on July 29, 2026, the Board approved the following conditional appointments, each to become effective at the Effective Time: Brigette Roberts, M.D., age 50, was conditionally appointed as the Company's Chief Executive Officer and will serve as the Company's Principal Executive Officer upon her appointment.
• Dr. Roberts has served as the Company's Chief of Corporate Affairs and member of the Company's Board since the closing of the Acquisition.
• Prior to that, she served as the Chief Executive Officer and member of the Board of Directors of Orphai from May 2021 until the closing of the Acquisition, and prior to that she served as the Chief Medical Officer of Orphai from February 2021 until May 2021.
• Dr. Roberts holds a B.A. in Physics and Chemistry from Harvard University and an M.D. from New York University.

Appointed: Brigette Roberts, Director

Appointment of Directors In accordance with the Merger Agreement, on May 18, 2026, effective immediately after the Effective Time, Brigette Roberts, M.D., was appointed to the Board as a Class III director.

Also stated in this filing

• - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
• Dr. Brigette Roberts served as the Chief Executive Officer and member of the Board of Directors of Orphai from May 2021 until the closing of the Acquisition, and prior to that she served as the Chief Medical Officer of Orphai from February 2021 until May 2021.
• During her time at Orphai, Dr. Roberts built a differentiated pulmonary franchise centered on LAM-001, an inhaled formulation of rapamycin for pulmonary vascular and fibrotic lung diseases, initiated two Phase 2 studies of LAM-001, secured U.S. and EU orphan drug designations for LAM-001 across multiple indications and raised more than $45 million in new private investment.
• Prior to Orphai, Dr. Roberts served as Entrepreneur in Residence at Fortress Biotech from 2017 to January 2021 where she identified new assets to spin into new biotechnology companies.
• Prior to that, Dr. Roberts spent over 15 years as a healthcare investor and portfolio manager including at CDP Capital, Angel Lane Principal Strategies, YYC Capital (which she founded), Third Point, LLC and DKR Capital.
• Dr. Roberts also served as a director of Ligand Pharmaceuticals (Nasdaq: LGND) from December 2005 to February 2007.

Reported

On April 22, 2026, the Board of Directors (the "Board") of Quince Therapeutics, Inc. (the "Company") increased the number of directors on the Board to four and appointed June Bray as a Class I director of the Company to fill the resulting vacancy, effective immediately, to serve until the 2026 Annual Meeting of Stockholders, or until her earlier death, disqualification, resignation or removal.

Also stated in this filing

• The Board has determined that Ms. Bray is an independent director under the listing standards of the Nasdaq Stock Market.
• Ms. Bray was also appointed to serve on the Nominating & Governance Committee, Audit Committee, and Compensation Committee of the Board.
• In accordance with the Policy, Ms. Bray is entitled to receive a $38,000 annual retainer for service as a Board member, plus $7,500, $5,500, and $4,000 annual retainers for her service on the Nominating & Governance Committee, Audit Committee, and Compensation Committee of the Board.